

Cover Story
Conversation with The Cancer Letter
FDA officials said the questions about accelerated approval of PD-1 and PD-L1 drugs have been largely resolved, thanks in part to guidance from the Oncologic Drugs Advisory Committee.
In Brief


Clinical Roundup


Drugs & Targets


Trending Stories
- UCSD’s Comprehensive Cancer Center designation is in trouble; director Califano steps down amid turmoil
- Richard Pazdur discusses root causes of cisplatin and carboplatin shortage and what can be done to alleviate it
- Robert Winn tells us how he led VCU Massey to obtain Comprehensive designation
- Cisplatin, carboplatin shortage prompts rationing of lifesaving drugs—patients will die
- Sexual harassers should face consequences: As NIH director, Bertagnolli can foster change
- Ezra Cohen named chief medical officer of oncology at Tempus